Nemaura Medical (NSDQ:NMRD) announced that it intends to offer shares of its common stock and warrants in a “best efforts” public offering. The Loughborough, England-based wearable diagnostic device developer for people with diabetes said in a news release that the offering includes an aggregate of up to nearly 1.6 million shares of common stock and warrants […]
Nemaura Medical (NSDQ:NMRD) announced today that it commissioned the integration of data to its ProBeat app set for U.S. launch this year. Data from third-party wearable devices can now be integrated into the ProBeat system, which is a wearable, non-invasive glucose monitor designed to gather big data centered around factors that affect blood glucose levels, according […]
Wearable diagnostic device developer Nemaura Medical (NSDQ:NMRD) announced today that it secured a $5 million non-convertible loan. The Loughborough, England–based company currently commercializing the SugarBeat continuous glucose monitor (CGM) received the 24-month loan, which does not include warrants or other equity securities, from Chicago Venture Partners, according to a news release. “This loan strengthens our financial […]
Nemaura Medical (NSDQ:NMRD) announced today that it is planning to immediately repurpose its SugarBeat continuous glucose monitor (CGM) as a continuous temperature monitor (CTM) to help diagnose fevers in potential cases of COVID-19. The Loughborough, England-based company said in a news release that its inbuilt temperature sensor is capable of continuously tracking body temperature through the […]
Nemaura Medical (NSDQ:NMRD) announced today that it entered into multiple verbal non-binding agreements for its SugarBeat continuous glucose monitor as it seeks to secure regional and global partnerships. The Loughborough, U.K.–based company expects the agreements to lead to discussions over licensing and collaboration, but can’t guarantee that deals will be struck as planned, or at all, […]
Nemaura Medical (NSDQ:NMRD) announced that it launched its SugarBeat app for continuous glucose monitoring on Android devices in the Play Store as it prepares to debut a subscription-based service. The Loughborough, England–based company’s SugarBeat is a non-invasive and flexible CGM designed to pair with BeatDiabetes, the company’s planned health subscription service for people with Type 2 […]
Nemaura Medical (NSDQ:NMRD) this week said it submitted a De Novo medical device applications to the FDA for its SugarBEAT non-invasive glucose monitor. The Loughborough, England-based company recently successfully completed clinical studies and two summative human factors usability studies needed to support De Novo submission. Get the full story on our sister site, Drug Delivery Business.
Nemaura Medical (NSDQ:NMRD) said yesterday that it won CE Mark approval for its SugarBEAT continuous glucose monitor. The SugarBEAT CGM is a flexible, disposable patch that’s connected to a rechargeable transmitter and Bluetooth-enabled smartphone app, designed to deliver glucose readings at five-minute intervals throughout the day. The company says the device allows users to spend more […]
Nemaura Medical (NSDQ:NMRD) said this week that it priced a public offering of the company’s common stock and warrants, hoping to reel in $2.5 million in proceeds. The offering is slated to close today. Nemaura plans to use the offering’s proceeds to support the launch of its wearable glucose monitor in Europe, as well as the development of […]
Nemaura Medical (NSDQ:NMRD) said today that it successfully developed predictive algorithms to support alarm functions in its sugarBeat continuous glucose monitoring system. The England-based company touted that its device’s alarm functionality can predict a user’s glucose level five minutes in advance with 98% accuracy, 10 minutes in advance with 95% accuracy and 15 minutes in advance with 90% accuracy. […]
Nemaura Medical (NSDQ:NMRD) said today that it launched a study of its wearable glucose monitor in the hopes of winning regulatory approval in the U.S. The England-based company touted positive interim data from the study, focusing on the at-home use of the sugarBeat device. Get the full story at our sister site, Drug Delivery Business News.